Latest Xeltis News
Xeltis’ closes €10.5 million Series D financing
Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The funding was provided by existing institutional and private investors, including all venture capital funds [...]
Xeltis preclinical data extend potential of restorative approach to small diameter vessels
Positive preclinical results from the three different applications of Xeltis’ restorative small diameter blood vessels have been presented at 2019 International Symposium for Applied Cardiovascular Biology and Vascular Tissue Engineering in Zurich (CH). All [...]
Xeltis’ restorative technology at Biomaterials
Preclinical data on Xeltis’ restorative heart valves will illustrate supramolecular materials’ potential application in clinical practice at the Society for Biomaterials annual meeting on Thursday 4 April. Xeltis CTO Martijn Cox will present 2-year [...]
Xeltis’ CEO shares cardiovascular strategy at Biocapital
A cardiovascular strategy to best leverage the potential of its RestoreX™ technology platform has been shared by Xeltis CEO Eliane Schutte at Biocapital Europe meeting in Amsterdam today. The company is moving forward with [...]
Xeltis’ RestoreX™ in Cardiovascular Pathology
Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to the paper, preclinical results of RestoreX™ pulmonary graft confirmed the potential of Xeltis’ restorative cardiovascular [...]
Xeltis’ new leadership functional to next phase
Mohammed El-Kurdi, PhD, Vice President for Tissue Science, and Luc Verhees, Senior Vice President for Clinical, Pre-clinical and Medical Affairs, joined Acting CEO Eliane Schutte - Xeltis CDO since 2016 - and CTO and Co-founder [...]
Xeltis data shortlisted at EACTS Techno-College Innovation Award
An abstract on Xeltis clinical data has been shortlisted as one of five finalists at the EACTS Techno-College Innovation Award. Professor Tomasz Mroczek from the Children’s University Hospital, Krakow, Poland will present 1-year Xeltis data [...]
Xeltis’ aortic valve one of highest peer-review oral abstracts at TCT
Initial in vivo experience on Xeltis’ restorative aortic valve will feature as one of the highest peer-reviewed oral abstracts of TCT 2018. Professor Christian Spaulding, Chief, Interventional Cardiology, European Hospital Georges Pompidou, Paris (F), will [...]